Judith A. Dunn
Independent DirectorDr. Judith A. Dunn, also known as Judy, Ph.D., is Atlas Advisor of Atlas Venture Advisors, Inc. from January 2026. Dr. Dunn was Entrepreneur-in-Residence of Atlas Venture Advisors, Inc. until January 2026. Dr. Dunn Served as President and Head of Research & Development of Vima Therapeutics, Inc until March 2026 and serves as President of Research & Development from March 2026. Dr. Dunn is Director of BioIVT, LLC from July 2024. She served as President of Research and Development at Fulcrum Therapeutics, Inc. since April 01, 2021 until October 14, 2022 and served as its Interim Chief Medical Officer since July 13, 2022 until January 03, 2023. Dr. Dunn serves as Independent Director at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) since February 2021. Dr. Dunn had been Director at Seelos Therapeutics, Inc. since May 15, 2020 until September 1, 2021. From March 2018 to April 2021, she served as Entrepreneur in Residence at Atlas Ventures. She was President of R&D at StealthNewCo. Dr. Dunn is Head of R&D at Sophren. She is an EIR focused on identifying new treatments in psychiatry. From 2010 to 2018, Dr. Dunn served as Vice President of Clinical Development for F. Hoffmann-La Roche and Head of Roche Innovation Center in NYC. She has served on the Scientific Advisory Board of the TRI TDI and is an advisor to the Empire Discovery Institute. She has served as an entrepreneur in residence at Atlas Venture since June 2018. Prior to that, she served in various roles at F. Hoffman-La Roche AG from March 2010 through January 2018, including Vice President, Global Head of Clinical Development and Principal Medical Group Leader, Neuroscience. Dr. Dunn also served as the Executive Medical Director, CNS Clinical Development (Ph I-III) at Sepracor, Inc. from 2005 to 2010, where she led Psychiatry Clinical Development. and held research and commercial positions at Pfizer Inc. from 1997 to 2005, including Director, Worldwide Medical Affairs, Antipsychotics, Senior Associate Director, Global Candidate Leader, CNS Development and Associate Director, CNS Development. She has served as the independent Board Member of Evolution Research Group since August 2018, as a Member of the NYC Mayor's Advisory Council on Life Sciences since December 2016 and as a Member of the Digital Health Breakthrough Network Advisory Board since 2017. Prior to that, she served as the Chairman of the Board of NYBIO from June 2016 to June 2018, as a Board Member of the Swiss American Foundation from January 2014 to January 2018, as a Board Member of the Partnership for NY Fund from 2014 to 2016 and as a Board Member of BioHealth Innovation Maryland from 2014 to 2015. Dr. Dunn received a Postdoctoral Fellowship in New Drug Development from Pfizer, a Training Fellowship in Neuropharmacology from the Center for Brain Research, a Doctor of Philosophy in Neurobiology from Wesleyan University and a Bachelor of Science, Neurobiology from the University of Rochester.
Positions
- Company NameClimb Bio, Inc.Stock CodeCLYMPositionIndependent DirectorColleagues
- AMAoife M. BrennanCEO, President & Director
- DEDouglas Edward WilliamsIndependent Chairman of the Board
- SASusan AltschullerCFO & Principal Accounting Officer
- PWPerrin WilsonChief Business Officer
- AVAdam VillaSenior Vice President of Technical Operations
- CAChandra AdamsSenior VP, General Counsel & Secretary
- AGAlexander G. CumboIndependent Director
- KCKimberlee Cobleigh DrapkinIndependent Director
